A Phase 3, Randomized, Multi-center, Blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin Versus Placebo to Manage Pain in Patients With Osteoarthritis of the Knee Whose Total Knee Replacement Surgery is Delayed
Latest Information Update: 12 Nov 2021
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Sorrento Therapeutics
Most Recent Events
- 02 Nov 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Oct 2020 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.
- 19 Oct 2020 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2022.